XRCC2 Antibody (3C190): sc-73278
- XRCC2 Antibody (3C190) is a mouse monoclonal IgG1, cited in 1 publications, provided at 200 µg/ml
- raised against human XRCC2
- recommended for detection of XRCC2 of human origin by WB
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for XRCC2 Antibody (3C190). This work is in progress.
QUICK LINKS
XRCC2 Antibody (3C190) is a mouse monoclonal IgG1 antibody that detects XRCC2 in human samples through western blotting (WB). XRCC2 plays a crucial role in maintaining genomic stability by participating in the repair of DNA double-strand breaks via homologous recombination, a vital process for accurate DNA repair during cell division. XRCC2 is primarily located in the nucleus, where XRCC2 interacts with other key proteins involved in the DNA repair machinery, such as Rad51, to facilitate the repair process. XRCC2′s nuclear localization ensures repair mechanisms are efficiently executed at the site of damage, thereby preventing genomic instability that could lead to various diseases, including cancer. Deficiencies in XRCC2 can result in increased sensitivity to DNA-damaging agents and contribute to the development of disorders associated with defective DNA repair. Anti-XRCC2 antibody (3C190) is an essential tool for researchers studying the mechanisms of DNA repair and the implications of XRCC2 in cellular health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
XRCC2 Antibody (3C190) References:
- XRCC2 is a nuclear RAD51-like protein required for damage-dependent RAD51 focus formation without the need for ATP binding. | O'Regan, P., et al. 2001. J Biol Chem. 276: 22148-53. PMID: 11301337
- Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. | Tsaryk, R., et al. 2006. Cancer Lett. 239: 305-13. PMID: 16298473
- The importance of XRCC2 in RAD51-related DNA damage repair. | Tambini, CE., et al. 2010. DNA Repair (Amst). 9: 517-25. PMID: 20189471
- Association of reduced XRCC2 expression with lymph node metastasis in breast cancer tissues. | Bashir, N., et al. 2014. Fam Cancer. 13: 611-7. PMID: 25159888
- Analysis of XRCC2 and XRCC3 gene polymorphisms in pancreatic cancer. | Talar-Wojnarowska, R., et al. 2016. Biomed Rep. 4: 236-240. PMID: 26893845
- Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility Gene XRCC2. | Hilbers, FS., et al. 2016. Hum Mutat. 37: 914-25. PMID: 27233470
- Impact of a Missense Variation (p.S150R:AGC>AGG) in the XRCC2 Gene on Susceptibility to Colorectal Cancer. | Sadat-Larijani, M., et al. 2018. Clin Lab. 64: 233-237. PMID: 29739106
- A PRISMA-compliant meta-analysis on association between X-ray repair cross complementing (XRCC1, XRCC2, and XRCC3) polymorphisms and oral cancer susceptibility. | Mozaffari, HR., et al. 2021. Gene. 781: 145524. PMID: 33631241
- Correlation analysis between XRCC2 polymorphism and radiosensitivity of non-small cell lung cancer. | He, Y., et al. 2021. Panminerva Med.. PMID: 34486365
- Association of RAD51, XRCC1, XRCC2, and XRCC3 Polymorphisms with Risk of Breast Cancer. | Gupta, P., et al. 2023. Genet Test Mol Biomarkers. 27: 205-214. PMID: 37522793
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
XRCC2 Antibody (3C190) | sc-73278 | 200 µg/ml | $322.00 |